Argenx and zai lab announce approval of vyvgart hytrulo for chronic inflammatory demyelinating polyneuropathy in china

First and only nmpa-approved treatment for patients with cidp in china  second vyvgart hytrulo indication approved in china  november 11, 2024 – 7:30am et  amsterdam, the netherlands— argenx se (euronext & nasdaq: argx) and zai lab limited (nasdaq: zlab; hkex: 9688) today announced that china's national medical products administration (nmpa) approved the supplemental biologics license application (sbla) for vyvgart hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (cidp). vyvgart hytrulo is approved for cidp as a once weekly 30-to-90 second subcutaneous injection.
ARGX Ratings Summary
ARGX Quant Ranking